Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Freiburg, Germany, October 12, 2021
Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates.
Its recently expanded production capacity enables Eleva to conduct clinical studies of its drug candidates. Among the first ones is factor H which will be developed all the way through phase II. Up to 2,500 l will be produced in state-of-the-art single-use reactors with improved LED technology at a GMP site. Eleva’s moss-based platform offers unique advantages for recombinant protein development, such as:
- Moss glycostructure naturally lacks core α-1,3 fucose – a known allergen – while any other glycans can be “humanized”. This leads to excellent organ uptake, as demonstrated in clinical studies.
- Being a plant, it will not be contaminated with animal pathogens, which eliminates the need for antibiotics.
- The moss production system, haploid by nature, is based on an intact organism, not on cell cultures. This guarantees exceptionally reliable and stable modifications.
Phone: +49 761 470 99 0
Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases.